Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • News
    • Financial Results
    • GSK Pharma reports Q2...

    GSK Pharma reports Q2 profit at Rs 503 crore

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-11-01T09:15:19+05:30  |  Updated On 16 Aug 2021 5:13 AM GMT

    GSK Pharmaceuticals continues to drive improved operational efficiencies reflecting in earnings before interest, tax, depreciation and amortisation (EBITDA) margin improving by 2 percentage points to 22 per cent.


    Mumbai: GlaxoSmithKline (GSK) Pharmaceuticals on Tuesday reported revenue for the quarter ended September 30 at Rs 873 crore with a year-on-year growth of 8 per cent.


    Profit after tax (PAT) including exceptional items came at Rs 503 crore, clocking a growth of 399 per cent. Exceptional items recognised in the quarter include divestment of the company's land at Thane for a net consideration of Rs 552 crore.


    Managing Director A Vaidheesh said the company's global innovation, performance and trust strategy guided investment of resources in focus therapies which is showing encouraging results with promoted brands recording over 20 per cent growth this quarter.


    "We continue to see the annualising effect of discontinued tail-end brands. Adjusting for this our underlying sales growth is 16 per cent supported by strong volume growth of 11 per cent," he said in a statement.


    Read Also: GSK to sell anti-rabies vaccines Rabipur, Encepur to Bavarian Nordic for USD 1.1 billion


    GSK Pharmaceuticals continues to drive improved operational efficiencies reflecting in earnings before interest, tax, depreciation and amortisation (EBITDA) margin improving by 2 percentage points to 22 per cent.


    During the quarter, GSK made the decision to suspend the release, distribution and supply of all dose forms of ranitidine hydrochloride products to all markets, including India, as a precautionary action pending the outcome of ongoing tests and investigations.


    Further to additional information received and as a precautionary action, the company decided to initiate a voluntary pharmacy and retail level recall of the Zinetac products from the Indian market. "Patient safety remains our utmost priority and we are taking this issue very seriously," it said.


    Read Also: GSK collaborates with Lyell Immunopharma on cancer cell therapies

    A Vaidheesh amortisation EBITDA GlaxoSmithKline GSK GSK Pharma GSK profit gsk revenue PAT pharmacy Q2 revenue ranitidine voluntary pharmacy Zinetac 
    Source : ANI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier

      This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:

      Search only trustworthy HONcode health websites:

      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2020 Minerva Medical Treatment Pvt Ltd

      © 2020 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      X